Asphalion Contributes to a Joint EU Policy Brief Supporting a Greener Pharmaceutical Future

This week, our regulatory experts, Maria Castellà and Alejandro Ballester, participated in the first consortium meeting of

The objective of this project is to create a siRNA-combined advanced therapy, which will allow a more personalised treatment for the different stages of osteoarthritis. All siNPAIN partners are working hard to develop an efficient therapy to improve the quality of life of those affected by osteoarthritis, a chronic joint condition that affects more and more people every year.

Last month, our colleagues Sergio Veiga and Marta Rayo represented ASPHALION at the Nabiheal Consortium Meeting, where project partners came

Last week in Siena, we joined the partners of the IMMUTOL project for its 3rd Annual Meeting

Within the EU-funded ETERNAL project, where Asphalion serves as the regulatory partner, supporting the consortium to ensure